SALT
LAKE CITY, June 14, 2023 /PRNewswire/ -- Lipocine
Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on
treating Central Nervous System (CNS) disorders by leveraging its
proprietary platform to develop differentiated products, today
announced that Dr. Mahesh Patel,
President and Chief Executive Officer, will present virtually and
meet with investors at the H.C. Wainwright 4th Annual
Neuropsychiatry Virtual Conference on June
26, 2023.
Presentation
Details
|
|
Time:
|
Available from 7:00
a.m. EDT onwards
|
Date:
|
June 26,
2023
|
Webcast
Link:
|
https://journey.ct.events/view/b86b23a9-2a90-40a7-8042-6c9540092369
|
The webcast link will be available for 90 days.
Investors can register for the conference here. Those interested
in arranging a 1x1 meeting with Lipocine should contact their H.C.
Wainwright representative.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its
proprietary technology platform to augment therapeutics through
effective oral delivery to develop products for CNS disorders.
Lipocine has drug candidates in development as well as drug
candidates for which we are exploring partnering. Our drug
candidates represent enablement of differentiated, patient friendly
oral delivery options for favorable benefit to risk profile which
target large addressable markets with significant unmet medical
needs.
Lipocine's clinical development candidates include: LPCN 1154,
oral brexanolone, for the potential treatment of postpartum
depression, LPCN 2101 for the potential treatment of epilepsy and
LPCN 1148, a novel androgen receptor agonist prodrug for oral
administration targeted for the management of symptoms associated
with liver cirrhosis. Lipocine is exploring partnering
opportunities for LPCN 1107, our candidate for prevention of
preterm birth, LPCN1154, for rapid relief of postpartum depression,
LPCN 1148, for the management of decompensated cirrhosis, LPCN
1144, our candidate for treatment of non-cirrhotic NASH, and LPCN
1111, a once-a-day therapy candidate for testosterone replacement
therapy (TRT). TLANDO, a novel oral prodrug of testosterone
containing testosterone undecanoate developed by Lipocine, is
approved by the FDA for conditions associated with a deficiency of
endogenous testosterone, also known as hypogonadism, in adult
males. For more information, please visit www.lipocine.com.
Forward-Looking
Statements
This release contains "forward-looking statements" that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not
historical facts regarding our product development efforts, the
application of our proprietary platform in developing new
treatments for CNS disorders, our product candidates and related
clinical trials, and the potential uses and benefits of our product
candidates. Investors are cautioned that all such forward-looking
statements involve risks and uncertainties, including, without
limitation, the risks that we may not be successful in developing
product candidates to treat CNS disorders, we may not have
sufficient capital to complete the development processes for our
product candidates, we may not be able to enter into partnerships
or other strategic relationships to monetize our non-core assets,
the FDA will not approve any of our products, risks related to our
products, expected product benefits not being realized, clinical
and regulatory expectations and plans not being realized, new
regulatory developments and requirements, risks related to the FDA
approval process including the receipt of regulatory approvals and
our ability to utilize a streamlined approval pathway for LPCN
1154, the results and timing of clinical trials, patient acceptance
of Lipocine's products, the manufacturing and commercialization of
Lipocine's products, and other risks detailed in Lipocine's filings
with the SEC, including, without limitation, its Form 10-K and
other reports on Forms 8-K and 10-Q, all of which can be obtained
on the SEC website at www.sec.gov. Lipocine assumes no
obligation to update or revise publicly any forward-looking
statements contained in this release, except as required by
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lipocine-to-present-at-hc-wainwright-annual-neuropsychiatry-virtual-conference-301850204.html
SOURCE Lipocine Inc.